These preliminary studies suggest a potential therapeutic effect of oral administration of GSH in NAFLD
Neurological: convulsions, increased intracranial pressure with papilledema (pseudotumor cerebri) usually after treatment, vertigo, headache Endocrine: menstrual irregularities, development of cushingoid state, suppression of fetal intrauterine or childhood growth, lack of secondary response of the adrenal cortex or pituitary gland, particularly in situations of stress such as trauma, surgery or illness, decreased carbohydrate tolerance, manifestations of latent diabetes mellitus, increased requirements of insulin or oral hypoglycemic agents in diabetic patients Ophtalmic: posterior subcapsular cataracts, increased intraocular pressure, glaucoma, exophthalmos Metabolic: negative nitrogen balance due to protein catabolism Psychiatric: euphoria, mood swings, severe depression to frank psychotic manifestations, personality changes, hyperirritability, insomnia Others: anaphylactoid or hypertensive reactions and hypotension or shock-like reaction Cyanocobalamin and hydroxocobalamin: hypervitaminosis and side effects were not observed with their use Dosage and administration Adults Coated tablets: 1 coated tablet 2 times a day
If you have any complaints or copyright issues related to this article, kindly contact the author above.
ABCD1 is also called VLCFA-CoA synthetase
Its efficacy is demonstrated through the reduction of liver fat, improvement of liver function markers, and regulation of specific genes such as Atf3 and Acox2, supporting its development as a targeted therapy (82)
